Teleflex Inc. (TFX) said that it receives FDA 510(k) clearance for Antithrombogenic claims on its ARROW peripherally inserted central catheter or PICC with Chlorag+ard Technology.
Teleflex said that in addition to broad-spectrum antimicrobial protection, the pressure-injectable ARROW PICC with Chlorag+ard Technology provides antithrombogenic protection for at least 30 days.
The company said that Chlorag+ard technology uses a proprietary formulation and process providing a controlled release and availability of chlorhexidine on catheter surfaces. The initial FDA cleared claim of 99.99% colonization reduction for at least 30 days against bacterial and fungal pathogens has now been enhanced by the certain ground-breaking claims.
The claims are 61% reduction in thrombus accumulation on catheter surfaces after 30 days; When challenged with infection, 92% reduction in thrombus accumulation on catheter surfaces after 30 days; Reduced thrombotic intraluminal occlusion; Reduction in phlebitis and an average of 72% less intimal hyperplasia after 30 days.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.